Muscarinic receptor type-3 in hypertension and cholinergic-adrenergic crosstalk: genetic insights and potential for new antihypertensive targets

Rhéure Alves-Lopes, Karla B. Neves, Rhian M. Touyz*

*Corresponding author for this work

Research output: Contribution to journalEditorialpeer-review

7 Citations (Scopus)
21 Downloads (Pure)

Abstract

Hypertension is a major risk factor for heart disease, renal failure, stroke, and vascular dementia and is the single most important cause of mortality worldwide.1 High blood pressure is easily detected and many effective and inexpensive antihypertensive drugs are available. It is a reversible condition and when appropriately treated, cardiovascular events are significantly reduced. However, hypertension remains a major challenge globally, with 30%-35% of adults having hypertension of whom less than 30% are treated and of those only a small proportion (10%-20%) are adequately controlled.2 Numerous factors contribute to these disappointing statistics including the fact that exact mechanisms that cause hypertension remain elusive.
Original languageEnglish
Pages (from-to)555-557
Number of pages3
JournalCanadian Journal of Cardiology
Volume35
Issue number5
Early online date12 Feb 2019
DOIs
Publication statusPublished - 1 May 2019

Funding

R.M.T. is supported by a British Heart Foundation Chair award ( CH/4/29762 ). K.N. and R.A.-L. are supported by the British Heart Foundation Award of Research Excellence ( RE/13/5/30177 ).

Keywords

  • editorial
  • muscarinic receptor
  • type-3
  • hypertension
  • cholinergic-adrenergic crosstalk
  • genetic insights
  • new antihypertensive targets

Fingerprint

Dive into the research topics of 'Muscarinic receptor type-3 in hypertension and cholinergic-adrenergic crosstalk: genetic insights and potential for new antihypertensive targets'. Together they form a unique fingerprint.

Cite this